Cumberland Pharmaceuticals (CPIX)
(Delayed Data from NSDQ)
$1.31 USD
+0.03 (2.34%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 +0.04 (3.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMCompany Summary
Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company's lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients.
Company Summary
General Information
Cumberland Pharmaceuticals Inc
1600 WEST END AVENUE SUITE 1300
NASHVILLE, TN 37203
Phone: 615-255-0068
Fax: 615-255-0094
Web: http://www.cumberlandpharma.com
Email: investors@cumberlandpharma.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Exp Earnings Date | NA |
EPS Information
Current Quarter EPS Consensus Estimate | NA |
Current Year EPS Consensus Estimate | NA |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | NA |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 1.28 |
52 Week High | 2.36 |
52 Week Low | 1.20 |
Beta | 0.20 |
20 Day Moving Average | 18,793.75 |
Target Price Consensus | 0.00 |
4 Week | 1.55 |
12 Week | -11.49 |
YTD | -26.89 |
4 Week | -1.75 |
12 Week | -16.21 |
YTD | -40.03 |
Shares Outstanding (millions) | 14.10 |
Market Capitalization (millions) | 18.47 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -100.00% |
vs. Previous Quarter | 100.00% |
vs. Previous Year | -9.55% |
vs. Previous Quarter | 15.90% |
Price/Book | 0.71 |
Price/Cash Flow | 1.89 |
Price / Sales | 0.49 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -6.86 |
3/31/24 | 0.21 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -2.46 |
3/31/24 | 0.08 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 1.44 |
3/31/24 | 1.37 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 1.26 |
3/31/24 | 1.21 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -5.36 |
3/31/24 | 0.18 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -27.45 |
3/31/24 | -21.67 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -27.30 |
3/31/24 | -21.52 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 1.83 |
3/31/24 | 1.92 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 1.20 |
3/31/24 | 0.90 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.62 |
3/31/24 | 0.59 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 38.20 |
3/31/24 | 37.17 |